Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound

J Infect Dis. 2002 Aug 1;186(3):445-6. doi: 10.1086/341461.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / virology
  • Cohort Studies
  • HIV / growth & development
  • HIV / immunology*
  • HIV / metabolism
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • Humans
  • Italy
  • Longitudinal Studies
  • RNA, Viral / blood
  • Viremia / drug therapy
  • Viremia / immunology
  • Viremia / virology

Substances

  • RNA, Viral